The use of cannabidiol in the treatment of epilepsy in neuropediatric: a review of the new contributions
Bibliographic record
Abstract
Background: Therapeutic cannabinoids are derived from marijuana, a plant of the cannabis genus. Cannabis sativa and Cannabis indica are the two main species. Cannabis plants contain more than 100 cannabinoids, but the biologically active and therapeutically researched ones are 9 tetrahydrocannabinol (THC) and cannabinol (CBD). Cannabinoids have been advocated for a number of neurological and psychiatric disorders, including multiple sclerosis, mood disorders, schizophrenia, Parkinson’s disease, dystonia, neuropathic pain, nausea, anorexia and epilepsy. Epilepsy is a chronic disease characterized by recurrent unprovoked seizures, affecting more than 50 million people worldwide, in the pediatric age group, with childhood epilepsy being one of the most serious and developing epileptic encephalopathies. Objective: In view of the above, the present study proposed to review the use of cannabidiol in the treatment of epilepsy in neuropediatric, with sources published between 2016-2020. Methods: To perform this research, PubMed (https://pubmeed.ncbi.nlm.nih. gov/) and Scielo (https://www.scielo.org/) databases were used as a search tool, using the Key words “Cannabidiol”, “Epilepsy”, “Cannabis” and “Children”. Results: So far, 11 articles related to the study have been identified, the vast majority being reviewed, with 9 articles obtained from PubMed and 2 acquired from Scielo. Selected articles show that CBD is an effective anticonvulsant in many acute animal models, but its antiepileptic mechanisms are not yet fully recognized. In studies with children in Canada and the United States, they suggest an improvement in the frequency of seizures and an improvement in quality of life, but the numbers are still small. Studies report that CBD is well tolerated, however, it causes sedation, diarrhea and decreased appetite. Conclusions: It is necessary to investigate the safety, pharmacokinetics and interaction between drugs already used by patients and CBD, also conducting more double-blind placebo-controlled trials to obtain conclusive data on their efficacy and safety in the most frequent epilepsies in children.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.007 | 0.006 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".